Cargando…

Cost of AF Ablation: Where Do We Stand?

Atrial fibrillation (AF) is a common and frequently disabling chronic condition associated with significant patient morbidity and affecting an increasing stratum of our ageing society. Direct costs related to atrial fibrillation are comprised from direct cost of medical therapy, catheter ablation, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Khaykin, Yaariv, Shamiss, Yana
Formato: Texto
Lenguaje:English
Publicado: SAGE-Hindawi Access to Research 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051175/
https://www.ncbi.nlm.nih.gov/pubmed/21403880
http://dx.doi.org/10.4061/2011/589781
_version_ 1782199451147829248
author Khaykin, Yaariv
Shamiss, Yana
author_facet Khaykin, Yaariv
Shamiss, Yana
author_sort Khaykin, Yaariv
collection PubMed
description Atrial fibrillation (AF) is a common and frequently disabling chronic condition associated with significant patient morbidity and affecting an increasing stratum of our ageing society. Direct costs related to atrial fibrillation are comprised from direct cost of medical therapy, catheter ablation, and related hospitalizations and imaging procedures, with indirect costs related to complications of the primary therapeutic strategy, management of related conditions, as well as disability and loss in quality of life related to AF. Over the last decade, catheter ablation became a promising alternative to rate and rhythm control among symptomatic AF patients. The purpose of this paper is to describe the evidence on the financial implications related to ablation based on published data and authors' experience.
format Text
id pubmed-3051175
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher SAGE-Hindawi Access to Research
record_format MEDLINE/PubMed
spelling pubmed-30511752011-03-14 Cost of AF Ablation: Where Do We Stand? Khaykin, Yaariv Shamiss, Yana Cardiol Res Pract Review Article Atrial fibrillation (AF) is a common and frequently disabling chronic condition associated with significant patient morbidity and affecting an increasing stratum of our ageing society. Direct costs related to atrial fibrillation are comprised from direct cost of medical therapy, catheter ablation, and related hospitalizations and imaging procedures, with indirect costs related to complications of the primary therapeutic strategy, management of related conditions, as well as disability and loss in quality of life related to AF. Over the last decade, catheter ablation became a promising alternative to rate and rhythm control among symptomatic AF patients. The purpose of this paper is to describe the evidence on the financial implications related to ablation based on published data and authors' experience. SAGE-Hindawi Access to Research 2011-03-03 /pmc/articles/PMC3051175/ /pubmed/21403880 http://dx.doi.org/10.4061/2011/589781 Text en Copyright © 2011 Y. Khaykin and Y. Shamiss. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Khaykin, Yaariv
Shamiss, Yana
Cost of AF Ablation: Where Do We Stand?
title Cost of AF Ablation: Where Do We Stand?
title_full Cost of AF Ablation: Where Do We Stand?
title_fullStr Cost of AF Ablation: Where Do We Stand?
title_full_unstemmed Cost of AF Ablation: Where Do We Stand?
title_short Cost of AF Ablation: Where Do We Stand?
title_sort cost of af ablation: where do we stand?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051175/
https://www.ncbi.nlm.nih.gov/pubmed/21403880
http://dx.doi.org/10.4061/2011/589781
work_keys_str_mv AT khaykinyaariv costofafablationwheredowestand
AT shamissyana costofafablationwheredowestand